4219-48-1

Basic information

• Product Name: 2-hydroxyethyl laurate
• Synonyms: 2-hydroxyethyl laurate;EGML Lubricant;2-Hydroxyethyl dodecanoate;Dodecanoic acid, 2-hydroxyethyl ester;LAURICACID,ETHYLENEGLYCOLMONOESTER;Ethylene glycol dodecanoate;Ethylene glycol laurate;Lauric acid 2-hydroxyethyl
• CAS NO: 4219-48-1
• Molecular Formula: C₁₄H₂₈O₃
• Molecular Weight: 244.37032
• EINECS: 224-159-2
• Mol File: 4219-48-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 31-32 °C
• Boiling Point: 352.3°C at 760 mmHg
• Flash Point: 136.9°C
• Appearance: /
• Density: 0.937g/cm³
• Vapor Pressure: 2.28E-06mmHg at 25°C
• Refractive Index: 1.451
• PKA: 13.90±0.10(Predicted)
• CAS DataBase Reference: 2-hydroxyethyl laurate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-hydroxyethyl laurate(4219-48-1)
• EPA Substance Registry System: 2-hydroxyethyl laurate(4219-48-1)

Safety Data

• Hazardous Substances Data: 4219-48-1(Hazardous Substances Data)

Usage

Uses

Ethylene Glycol Monolaurate was used as a reactant in the synthesis of neuritogenic gentiside derivatives.

InChI:InChI=1/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-14(16)17-13-12-15/h15H,2-13H2,1H3

Upstream product

• 143-07-7 lauric acid 
• 107-21-1 ethylene glycol 
• 5735-88-6 2-undecanyl-1,3-dioxolane 
• 108-95-2 phenol 
• 624-76-0 Iodoethanol 
• 112-16-3 n-dodecanoyl chloride 
• 52849-39-5 sulfuric acid mono-(2-lauroyloxy-ethyl ester); sodium-salt 
• 624-04-4 2-dodecanoyloxyethyl dodecanoate 
• 7664-93-9 sulfuric acid 
• 10124-65-9 potassium laurate 
• 107-07-3 2-chloro-ethanol 
• 959064-28-9 lauric acid-(2-iodo-ethyl ester) 
• 35438-71-2 triglycol borate 
• 75-21-8 oxirane 

Downstream Products

• 143-07-7 lauric acid 
• 6914-91-6 ethane-1,2-diyl bis(hydrogen sulfate) 
• 45260-28-4 sulfuric acid mono-(2-lauroyloxy-ethyl ester) 
• 1246886-32-7 C₂₆H₄₄ClO₅P 

Relevant articles and documents

Development and preclinical evaluation of new inhaled lipoglycopeptides for the treatment of persistent pulmonary methicillin-resistant staphylococcus aureus infections

Chronic pulmonary methicillin-resistant Staphylococcus aureus (MRSA) disease in cystic fibrosis (CF) has a high probability of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptide therapy customized for pulmonary delivery that not only demonstrates potent activity against planktonic MRSA, but also against protected colonies of MRSA in biofilms and within cells, the latter of which have been linked to clinical antibiotic failure. A library of next-generation potent lipoglycopeptides was synthesized with an emphasis on attaining superior pharmacokinetics (PK) and pharmacodynamics to similar compounds of their class. Our strategy focused on hydrophobic modification of vancomycin, where ester and amide functionality were included with carbonyl configuration and alkyl length as key variables. Candidates representative of each carbonyl attachment chemistry demonstrated potent activity in vitro, with several compounds being 30 to 60 times more potent than vancomycin. Selected compounds were advanced into in vivo nose-only inhalation PK evaluations in rats, where RV94, a potent lipoglycopeptide that utilizes an inverted amide linker to attach a 10-carbon chain to vancomycin, demonstrated the most favorable lung residence time after inhalation. Further in vitro evaluation of RV94 showed superior activity to vancomycin against an expanded panel of Gram-positive organisms, cellular accumulation and efficacy against intracellular MRSA, and MRSA biofilm killing. Moreover, in vivo efficacy of inhaled nebulized RV94 in a 48 h acute model of pulmonary MRSA (USA300) infection in neutropenic rats demonstrated statistically significant antibacterial activity that was superior to inhaled vancomycin.

Synthesis and SAR studies of neuritogenic gentiside derivatives

Tetradecyl 2,3-dihydroxybenzoate (ABG-001) has been designed and synthesised as a lead compound to treat Alzheimer's disease, based on structure-activity relationships of gentisides. In this paper, the alkyl chain and ester linkage group of ABG-001 were modified. Consequently, several series of novel gentiside derivatives were designed and synthesised, and their neuritogenic activity was evaluated in PC12 cells. Among all the tested compounds, S-dodecyl 2,3-dihydroxybenzothioate (15d, named as ABG-199) was the most potent; the compound induced significant neurite outgrowth at 0.1 μM, which was comparable to that of nerve growth factor at the optimal concentration of 40 ng/mL and ABG-001 at 1 μM. A brief study on the mechanism of action of ABG-199 revealed that extracellular signal-regulated kinase phosphorylation was involved in ABG-199-induced neurite outgrowth in PC12 cells.

PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS

This invention relates to compounds represented by the structural formula (I), and the salts and stereoisomers thereof, wherein: - L is a linker selected from the group consisting of -(CH2)P-O-, a single bond, formula (IA), -(CH2)1-8-O-X(O)-, and - p is an integer from 1 to 8, - each R3 and each R4 is independently selected from the group consisting of C1-20alkyl, C3-12alkyl, C3-12cycloalkyl-C1-4alkyl, saturated heterocyclyl and saturated heterocyclyl-C1-4alkyl, and - X and Y are each independently C or S(O), - Z is selected from the group consisting of O, S(O) and NR5, - W is selected from the group consisting of halogen, OH, S(O)H and O-M+ wherein M+ is a monovalent cation; and - R5 is selected from the group consisting of hydrogen and C1-10 alkyl. These compounds are useful pharmaceutical agents with improved oral bioavailability.